FDA removes clinical holds from several checkpoint inhibitor trials in myeloma

The U.S. Food and Drug Administration (FDA) has removed the partial clinical holds placed on several clinical trials investigating checkpoint inhibitors in combination with immunomodulatory drugs for myeloma patients. The Roche trial (NCT02431208) investigating atezolizumab (Tecentriq®) in combination with pomalidomide or lenalidomide for relapsed and refractory myeloma patients will now continue with protocol amendments as…

Details